Asahi Kasei Bioprocess Launches Planova™ S20N, Strengthening High Flux and Broad Adaptability Across Platforms
Asahi Kasei Medical Co., Ltd. is pleased to announce the commercial launch in October of Planova™ S20N, its next generation regenerated cellulose virus filter that's ready for any challenges. S20N promises "superior" filtration performance for various types of biopharmaceutical products, "secure" robust virus removal capability, and "simplified" operation for your post-use integrity test.
Asahi Kasei Medical is the global market leader in virus filtration, with its Planova™ filters having an unrivaled 30-year history of trusted use in the production of biotherapeutics. Asahi Kasei Medical aims to provide "Assurance Beyond Expectation" in the form of innovative yet exceptionally reliable bioprocess consumables, equipment, scientific support, and biosafety testing services to help biologics manufacturers safely and efficiently produce medicines that patients can trust.
By adding Planova™ S20N to its family of advanced virus removal filters, Asahi Kasei Medical endeavors to contribute to further improvement of operations and the greater safety of biologicals and to further driving the growth of the healthcare sector of the Asahi Kasei Group.